Bullous pemphigoid induced by gliptins

Authors

  • Marianela Geloso Francisco Javier Muñiz Hospital, Autonomous City of Buenos Aires, Argentina
  • María Emilia Candiz Franciso Javier Muñiz Hospital, Autonomous City of Buenos Aires, Argentina
  • Olga Forero Dr. Francisco Javier Muñiz Hospital, Autonomous City of Buenos Aires, Argentina
  • Liliana Olivares Dr. Francisco Javier Muñiz Hospital, Autonomous City of Buenos Aires, Argentina
  • Esteban Maronna Dr. Francisco Javier Muñiz Hospital, Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/da.v26i4.2156

Keywords:

gliptins, bullous pemphigoid, vildagliptin

Abstract

Gliptins are hypoglycemic drugs used to treat type 2 diabetes mellitus, as monotherapy or together with metformin. They were incorporated in 2006 and since then there have been multiple reported cases that demonstrate their association with bullous pemphigoid. We report a case of an 83-year-old patient with a diagnosis of vildagliptin-induced bullous pemphigoid.

Author Biographies

Marianela Geloso, Francisco Javier Muñiz Hospital, Autonomous City of Buenos Aires, Argentina

Concurrent Second Year Dermatology Medical Doctor. Dermatology Unit, Muñiz Hospital.

María Emilia Candiz, Franciso Javier Muñiz Hospital, Autonomous City of Buenos Aires, Argentina

Medical Doctor, Specialist in Dermatology. Dermatology Unit, Muñiz Hospital.

Olga Forero, Dr. Francisco Javier Muñiz Hospital, Autonomous City of Buenos Aires, Argentina

Medical Doctor, Specialist in Dermatology. Dermatology Unit, Muñiz Hospital.

Liliana Olivares, Dr. Francisco Javier Muñiz Hospital, Autonomous City of Buenos Aires, Argentina

Head of the Dermatology Unit, Muñiz Hospital.

Esteban Maronna, Dr. Francisco Javier Muñiz Hospital, Autonomous City of Buenos Aires, Argentina

Dermatopathologist. Dermatology Unit, Muñiz Hospital.

References

I. Stavropoulos P. G, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 2014;28:1133-1140.

II. Aylwin C. Nuevos fármacos en diabetes mellitus. Rev Med Clin Condes 2016:27:235-256.

III. Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, et ál. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermat Venereol 2012;26:249-253.

IV. García M, Aranburu M, Palacios-Zabalza I, Lertxundi U, et ál. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther 2016;41:368-370.

V. Reolid A, Muñoz-Aceituno E, Rodríguez-Jiménez P, González-Rojano E, et ál. Bullous pemphigoid associated with dipeptiyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database. Int J Dermatol 2020;59:197-206.

VI. García-Díez I, Ivars-Lleó M, López-Aventín D, Ishii N, et ál. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization. Int J Dermatol 2018;57:810-816.

VII. Phan K, Charlton O, Smith S. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis. Australas J Dermatol 2020;61:e15-e21.

VIII. Kridin K, Bergman R. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes. JAMA Dermatol 2018;154:1152-1158.

IX. Izumi K, Nishie W, Mai Y, Wada M, et ál. Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid. J Invest Dermat 2016;136:2201-2210.

X. Rodríguez L, Forero O, Olivares L, Candiz ME, et ál. Dermatosis por IgA lineal vinculada a fármacos. Dermatol Argent 2017;23:42-45.

Downloads

Published

2020-12-20

Issue

Vol. 26 No. 4 (2020): October-December 2020

Section

Clinical Cases

License

El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.

 

Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor